<DOC>
	<DOCNO>NCT00073502</DOCNO>
	<brief_summary>Multi-center , open-label , non-randomized Phase II study evaluate efficacy safety OSI-7904L gastric GEJ cancer . Those patient derive clinical benefit two cycle may switch commonly use combination regimen .</brief_summary>
	<brief_title>Phase II Study Single Agent OSI-7904L Patients With Gastric Gastroesophageal ( GEJ ) Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Documented locally advanced metastatic adenocarcinoma stomach gastroesophageal junction No prior chemotherapy locally advanced metastatic disease Adequate baseline bone marrow , hepatic renal function Age &gt; = 18 year At least one target lesion Active uncontrolled infection serious illness medical condition ( eg , hepatitis , HIV , chronic alcohol abuse ) Symptomatic brain metastasis stable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
</DOC>